$ADTX
Aditxt, Inc. Stock $adtx

$adtx Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000121390023087099 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q4
Revenue	$81.30K	$124.5K	$185.6K
YoY Change	-56.2%	-61.47%	76.71%
Cost Of Revenue	$285.9K	$106.9K	$170.2K
YoY Change	67.99%	-54.25%	118.22%
Gross Profit	-$204.6K	$17.56K	$15.43K
YoY Change	-1425.79%	-80.36%	-42.96%
Gross Profit Margin	-251.62%	14.11%	8.31%
Selling, General & Admin	$3.443M	$7.214M	$5.134M
YoY Change	-32.94%	84.45%	-77.0%
% of Gross Profit		41072.93%	33274.34%
Research & Development	$4.303M	$898.7K	$3.081M
YoY Change	39.66%	-42.78%	81.0%
% of Gross Profit		5116.85%	19969.15%
Depreciation & Amortization	$132.9K	$109.6K	$159.0K
YoY Change	-16.42%	-13.52%	22.51%
% of Gross Profit		624.07%	1030.72%
Operating Expenses	$7.746M	$8.113M	$8.215M
YoY Change	-5.71%	48.0%	-65.8%
Operating Profit	-$7.951M	-$8.095M	-$8.200M
YoY Change	-3.04%	50.13%	-65.82%
Interest Expense	-$3.079M	-$1.651M	$16.88K
YoY Change	-18338.45%	-23.77%	-128.71%
% of Operating Profit
Other Income/Expense, Net		-$1.651M	$0.00
YoY Change		-23.77%
Pretax Income	-$10.98M	-$9.746M	-$8.183M
YoY Change	34.15%	28.96%	-65.98%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$11.12M	-$9.746M	-$8.183M
YoY Change	35.9%	28.96%	-65.98%
Net Earnings / Revenue	-13678.87%	-7828.91%	-4409.04%
Basic Earnings Per Share		-$48.77
Diluted Earnings Per Share	-$15.10	-$47.95	-$1.96
COMMON SHARES
Basic Shares Outstanding	441.9K shares	7.611M shares	4.161M shares
Diluted Shares Outstanding		203.2K shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$97.10K	$1.651M	$2.769M
YoY Change	-96.49%	-82.14%	-64.83%
Cash & Equivalents	$97.10K	$1.651M	$2.769M
Short-Term Investments
Other Short-Term Assets	$217.4K	$555.6K	$496.9K
YoY Change	-56.25%	-19.41%	7.99%
Inventory	$745.5K	$858.1K	$950.1K
Prepaid Expenses	$217.4K	$555.6K	$496.9K
Receivables	$408.3K	$362.7K	$528.0K
Other Receivables	$5.445M	$0.00	$0.00
Total Short-Term Assets	$6.913M	$3.428M	$4.744M
YoY Change	45.73%	-72.85%	-49.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.099M	$2.004M	$2.319M
YoY Change	76.75%	-10.89%	2.27%
Goodwill
YoY Change
Intangibles	$9.444K	$26.75K	$107.0K
YoY Change	-91.17%
Long-Term Investments	$22.38M	$312.3K	$355.4K
YoY Change	6198.68%	-21.56%	-6.3%
Other Assets	$11.17M	$0.00
YoY Change		-100.0%
Total Long-Term Assets	$37.67M	$4.798M	$5.992M
YoY Change	528.63%	-26.81%	-17.32%
TOTAL ASSETS
Total Short-Term Assets	$6.913M	$3.428M	$4.744M
Total Long-Term Assets	$37.67M	$4.798M	$5.992M
Total Assets	$44.58M	$8.226M	$10.74M
YoY Change	315.25%	-57.11%	-35.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.555M	$4.224M	$1.959M
YoY Change	336.81%	55.77%	24.31%
Accrued Expenses	$999.9K	$1.081M	$1.087M
YoY Change	-7.98%	-3.69%	-5.11%
Deferred Revenue
YoY Change
Short-Term Debt	$16.03M	$4.020M	$0.00
YoY Change		4925.08%
Long-Term Debt Due	$147.8K	$147.8K	$410.0K
YoY Change	-63.94%	-40.09%	-41.47%
Total Short-Term Liabilities	$25.89M	$11.24M	$3.644M
YoY Change	610.53%	157.1%	1.01%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$2.642M	$1.204M	$1.885M
YoY Change	40.13%	-43.01%	-31.84%
Total Long-Term Liabilities	$2.642M	$1.204M	$1.885M
YoY Change	40.13%	-43.01%	-34.45%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.89M	$11.24M	$3.644M
Total Long-Term Liabilities	$2.642M	$1.204M	$1.885M
Total Liabilities	$28.52M	$12.45M	$5.529M
YoY Change	415.87%	91.92%	-14.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$127.7M	-$116.6M	-$95.04M
YoY Change	34.41%	34.31%	41.11%
Common Stock	$1.319K	$368.00	$4.307K
YoY Change	-69.38%	-90.14%	-90.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$201.6K	$201.6K	$201.6K
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares			2.017K shares
Shareholders Equity	$16.06M	-$4.222M	$5.206M
YoY Change
Total Liabilities & Shareholders Equity	$44.58M	$8.226M	$10.74M
YoY Change	315.25%	-57.11%	-35.58%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q4
OPERATING ACTIVITIES
Net Income	-$11.12M	-$9.746M	-$8.183M
YoY Change	35.9%	28.96%	-65.98%
Depreciation, Depletion And Amortization	$132.9K	$109.6K	$159.0K
YoY Change	-16.42%	-13.52%	22.51%
Cash From Operating Activities	-$3.309M	-$8.038M	-$6.720M
YoY Change	-50.75%	2.8%	-22.68%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$4.410K	$88.82K
YoY Change	-100.0%	-205.25%	-177.19%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$268.5K
YoY Change		-100.0%	-103.21%
Cash From Investing Activities	$0.00	-$4.410K	$179.7K
YoY Change	-100.0%	-105.04%	-102.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.755M	9.595M	64.01K
YoY Change	2641.77%	-40.67%	-99.67%
NET CHANGE
Cash From Operating Activities	-3.309M	-8.038M	-6.720M
Cash From Investing Activities	0.000	-4.410K	179.7K
Cash From Financing Activities	1.755M	9.595M	64.01K
Net Change In Cash	-1.554M	1.553M	-6.476M
YoY Change	-76.0%	-81.6%	-369.55%
FREE CASH FLOW
Cash From Operating Activities	-$3.309M	-$8.038M	-$6.720M
Capital Expenditures	$0.00	$4.410K	$88.82K
Free Cash Flow	-$3.309M	-$8.042M	-$6.809M
YoY Change	-51.4%	2.91%	-20.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Other Income OtherIncome		usd
CY2022Q3	us-gaap	Other Income OtherIncome		usd
	us-gaap	Other Income OtherIncome		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	157584	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39336
	dei	Entity Registrant Name EntityRegistrantName	Aditxt, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3204328
	dei	Entity Address Address Line1 EntityAddressAddressLine1	737 N. Fifth Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Richmond
	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	23219
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	870-1200
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ADTX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	441851	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1651354	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2768640	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	362708	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	527961	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	858106	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	950093	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	555631	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	496869	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	3427799	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4743563	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2003859	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2318863	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26750	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	107000	usd
CY2023Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	312265	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	355366	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2454886	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3160457	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	50000	usd
CY2023Q3	us-gaap	Assets Assets	8225559	usd
CY2022Q4	us-gaap	Assets Assets	10735249	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4224425	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1958502	usd
CY2023Q3	adtx	Notes Payable Related Party NotesPayableRelatedParty	4020055	usd
CY2023Q3	adtx	Financing Of Fixed Asset Long Term FinancingOfFixedAssetLongTerm	147823	usd
CY2022Q4	adtx	Financing Of Fixed Asset Long Term FinancingOfFixedAssetLongTerm	409983	usd
CY2023Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	169633	usd
CY2022Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	188581	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1081377	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1086658	usd
CY2023Q3	adtx	Settlement Liability Current SettlementLiabilityCurrent	1600000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11243313	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3643724	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1203876	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1885218	usd
CY2023Q3	us-gaap	Liabilities Liabilities	12447189	usd
CY2022Q4	us-gaap	Liabilities Liabilities	5528942	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	3000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	367902	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107698	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	367851	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	107647	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	368	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	108	usd
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	51	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	51	shares
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	201605	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	201605	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	112599764	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100448166	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116620157	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95040362	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-4221630	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5206307	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8225559	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10735249	usd
CY2023Q3	us-gaap	Revenues Revenues	124486	usd
CY2022Q3	us-gaap	Revenues Revenues	323125	usd
	us-gaap	Revenues Revenues	563879	usd
	us-gaap	Revenues Revenues	748119	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	106922	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	233684	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	470969	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	596613	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	17564	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	89441	usd
	us-gaap	Gross Profit GrossProfit	92910	usd
	us-gaap	Gross Profit GrossProfit	151506	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7169863	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3919618	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15209789	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12332728	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	898724	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1570540	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2771100	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4186842	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	44186	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	-8553	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	223562	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	911988	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	8112773	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	5481605	usd
	us-gaap	Operating Expenses OperatingExpenses	18204451	usd
	us-gaap	Operating Expenses OperatingExpenses	17431558	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8095209	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5392164	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18111541	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17280052	usd
CY2023Q3	us-gaap	Interest Expense Other InterestExpenseOther	906104	usd
CY2022Q3	us-gaap	Interest Expense Other InterestExpenseOther	645381	usd
	us-gaap	Interest Expense Other InterestExpenseOther	2389627	usd
	us-gaap	Interest Expense Other InterestExpenseOther	742701	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	367	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	10084	usd
	us-gaap	Interest Income Other InterestIncomeOther	9784	usd
	us-gaap	Interest Income Other InterestIncomeOther	30131	usd
	us-gaap	Other Income OtherIncome	58960	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	744956	usd
CY2022Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1530102	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	921242	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1533048	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1650693	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2165399	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3301085	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2186658	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9745902	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7557563	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21412626	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19466710	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9745902	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7557563	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21412626	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19466710	usd
CY2023Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	167169	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	167169	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9913071	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7557563	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21579795	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19466710	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-48.77
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-210.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-136.94
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-720.54
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	203247	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35829	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	157584	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27017	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5206307	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	59964	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	111187	usd
CY2023Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	507016	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	168300	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-5984706	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	68068	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	59964	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	103264	usd
CY2023Q2	adtx	Warrants Issued For Cash Net Of Issuance Costs WarrantsIssuedForCashNetOfIssuanceCosts	1581467	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-5682018	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-3869255	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	59964	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	94028	usd
CY2023Q3	adtx	Sale Of Preferred Shares To Related Party SaleOfPreferredSharesToRelatedParty	1000	usd
CY2023Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	272006	usd
CY2023Q3	adtx	Stock Issued During Periodfor Issuance Of Warrants For Offering Net Of Issuance Costs StockIssuedDuringPeriodforIssuanceOfWarrantsForOfferingNetOfIssuanceCosts	8966400	usd
CY2023Q3	adtx	Exercise Of Warrants ExerciseOfWarrants	129	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-9745902	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-4221630	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10180773	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	219885	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	377671	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3719	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-6059141	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4722907	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	724584	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	309704	usd
CY2022Q2	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1203769	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	250000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-5850006	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	1360958	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	338439	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	293119	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	20000	usd
CY2022Q3	adtx	Redemption Of Preferred Shares To Related Party RedemptionOfPreferredSharesToRelatedParty	20000	usd
CY2022Q3	adtx	Shares Issued As Inducement On Loans Net Of Issuance Costs SharesIssuedAsInducementOnLoansNetOfIssuanceCosts	146522	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	878622	usd
CY2022Q3	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	96030	usd
CY2022Q3	adtx	Stock Issued During Periodfor Issuance Of Shares And Warrants For Offering Net Of Issuance Costs StockIssuedDuringPeriodforIssuanceOfSharesAndWarrantsForOfferingNetOfIssuanceCosts	17232555	usd
CY2022Q3	adtx	Aggregate Amount AggregateAmount	94195	usd
CY2022Q3	adtx	Rounding From Reverse Stock Split RoundingFromReverseStockSplit	-13	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-7557563	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	12694474	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21412626	usd
	us-gaap	Net Income Loss NetIncomeLoss	-19466710	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	656671	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2517121	usd
	us-gaap	Depreciation Depreciation	329411	usd
	us-gaap	Depreciation Depreciation	296685	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80250	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80250	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	921242	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1533048	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-165253	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	229315	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	58762	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	18864	usd
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	-43101	usd
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	572966	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-91987	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	947729	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2315923	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1136448	usd
	adtx	Increase Decrease Settlement Liability IncreaseDecreaseSettlementLiability	1600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15267550	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15672032	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14407	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	278256	usd
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	87934	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	55454	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14407	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-421644	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	687523	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	80000	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	5962865	usd
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	3138888	usd
	adtx	Discount On Note Payable From Offering Costs DiscountOnNotePayableFromOfferingCosts	-411887	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	687523	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2592046	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3138888	usd
	adtx	Sale Of Preferred Shares To Related Party SaleOfPreferredSharesToRelatedParty	20000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10547867	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	507016	usd
	adtx	Common Stock And Warrants Issued For Cash Net Of Issuance Costs CommonStockAndWarrantsIssuedForCashNetOfIssuanceCosts	17232555	usd
	us-gaap	Profit Loss ProfitLoss	21412626	usd
	us-gaap	Interest Paid InterestPaid	15267550	usd
	adtx	Sale Of Series C Preferred Shares To Related Party SaleOfSeriesCPreferredSharesToRelatedParty	1000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	129	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1109574	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-262160	usd
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-563751	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14164671	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17466491	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1117286	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1372815	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2768640	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7872061	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1651354	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9244876	usd
	us-gaap	Interest Paid Net InterestPaidNet	1190332	usd
	us-gaap	Interest Paid Net InterestPaidNet	740301	usd
	adtx	Debt Discount From Warrants Issued With Convertible Note Payable DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable	878622	usd
	adtx	Debt Discount From Shares Issued As Inducement For Note Payable DebtDiscountFromSharesIssuedAsInducementForNotePayable	272006	usd
	adtx	Debt Discount From Shares Issued As Inducement For Note Payable DebtDiscountFromSharesIssuedAsInducementForNotePayable	174522	usd
	adtx	Shares Issued For Debt Offering Costs SharesIssuedForDebtOfferingCosts	96030	usd
	adtx	Redemption Of Series Preferred Shares To Related Party RedemptionOfSeriesPreferredSharesToRelatedParty	20000	usd
	adtx	Warrant Modification WarrantModification	167169	usd
	adtx	Warrant Modification WarrantModification	8619	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Company Background</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a biotech innovation company with a mission of prolonging life and enhancing its quality by improving the health of the immune system. We are an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. Our immune reprogramming technologies are currently at the pre-clinical stage and are designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. Our immune monitoring technologies are designed to provide a personalized comprehensive profile of the immune system and we plan to utilize them in our upcoming reprogramming clinical trials to monitor subjects’ immune response before, during and after drug administration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2023, the Company formed Adimune, Inc., a Delaware wholly owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 1, 2023, the Company formed Pearsanta, Inc., a Delaware wholly owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2023, the Company formed Adivir, Inc., a Delaware wholly owned subsidiary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reverse Stock Split</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “2022 Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on September 14, 2022. There was no change to the number of authorized shares of the Company’s common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2023, the Company effectuated a 1 for 40 reverse stock split (the “2023 Reverse Split”). The Company’s stock began trading on a split-adjusted basis effective on the Nasdaq Stock Market on August 18, 2023. There was no change to the number of authorized shares of the Company’s common stock. All share amounts referenced in this report are adjusted to reflect the 2023 Reverse Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Offerings</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 31, 2021, the Company completed a registered direct offering (“August 2021 Offering”). In connection therewith, the Company issued 2,292 shares of common stock, at a purchase price of $4,800.00 per share, resulting in gross proceeds of approximately $11.0 million. In a concurrent private placement, the Company issued warrants to purchase up to 2,292 shares. The warrants have an exercise price of $5,060.00 per share and are exercisable for a five-year period commencing months from the date of issuance. The warrants exercise price was subsequently repriced to $3,000.00. In addition, the Company issued a warrant to the placement agent to purchase up to 115 shares of common stock at an exercise price of $6,000.00 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 18, 2021, the Company entered into an underwriting agreement with Revere Securities LLC, relating to the public offering (the “October 2021 Offering”) of 1,417 shares of the Company’s common stock (the “Shares”) by the Company. The Shares were offered, issued, and sold at a price to the public of $3,000.00 per share under a prospectus supplement and accompanying prospectus filed with the SEC pursuant to an effective shelf registration statement filed with the SEC on Form S-3 (File No. 333-257645), which was declared effective by the SEC on July 13, 2021. The October 2021 Offering closed on October 20, 2021 for gross proceeds of $4.25 million. The Company utilized a portion of the proceeds, net of underwriting discounts of approximately $3.91 million from the October 2021 Offering to fund certain obligations of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 6, 2021, the Company completed a public offering for net proceeds of $16.0 million (the “December 2021 Offering”). As part of the December 2021 Offering, we issued 4,123 units consisting of shares of the Company’s common stock and warrant to purchase shares of the Company’s common stock and 4,164 prefunded warrants. The warrant issued as part of the units had an exercise price of $2,300.00 and the prefunded warrants had an exercise price of $0.04. On June 15, 2022, the Company entered an agreement with a holder of certain warrants in the December 2021 Offering. (See Note 10)</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 20, 2022, the Company completed a public offering for net proceeds of $17.2 million (the “September 2022 Offering”). As part of the September 2022 Offering, we issued 30,608 of shares of the Company’s common stock, pre-funded warrants to purchase 52,725 shares of common stock, and warrants to purchase 83,333 shares of the Company’s common stock. The warrants had an exercise price of $240.00 and the pre-funded warrants had an exercise price of $0.04.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 20, 2023, the Company entered into a securities purchase agreement (the “April Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to sell to such investor pre-funded warrants (the “April Pre-Funded Warrants”) to purchase up to 39,634 shares of common stock of the Company (the “Common Stock”) at a purchase price of $48.76 per April Pre-Funded Warrant. The April Pre-Funded Warrants (and shares of common stock underlying the April Pre-Funded Warrants) were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-257645), which was declared effective by the Securities and Exchange Commission on July 13, 2021. Concurrently with the sale of the April Pre-Funded Warrants, pursuant to the Purchase Agreement in a concurrent private placement, for each April Pre-Funded Warrant purchased by the investor, such investor received from the Company an unregistered warrant (the “Warrant”) to purchase two shares of Common Stock. The warrants have an exercise price of $34.40 per share, and are exercisable for a three year period. In addition, the Company issued a warrant to the placement agent to purchase up to 2,378 shares of common stock at an exercise price of $61.00 per share. The closing of the sales of these securities under the April Purchase Agreement took place on April 24, 2023. The gross proceeds from the offering were approximately $1.9 million, prior to deducting placement agent’s fees and other offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 31, 2023, the “Company entered into a securities purchase agreement (the “August Purchase Agreement”) with an institutional investor for the issuance and sale in a private placement (the “Private Placement”) of (i) pre-funded warrants (the “August Pre-Funded Warrants”) to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $0.001 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price of $10.00 per share. The Private Placement closed on September 6, 2023. The net proceeds to the Company from the Private Placement were approximately $9 million, after deducting placement agent fees and expenses and estimated offering expenses payable by the Company. The Company intends to use the net proceeds received from the Private Placement for (i) the payment of approximately $3.1 million in outstanding obligations, (ii) the repayment of approximately $0.4 million of outstanding debt, and (iii) the balance for continuing operating expenses and working capital.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Risks and Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has a limited operating history and is in the very early stages of generating revenue from intended operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide along with local, state, and federal governmental policy decisions. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: changes in the biotechnology regulatory environment, technological advances that render our technologies obsolete, availability of resources for clinical trials, acceptance of technologies into the medical community, and competition from larger, more well-funded companies. These adverse conditions could affect the Company’s financial condition and the results of its operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 30, 2020, the World Health Organization declared the COVID-19 novel coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus included restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 coronavirus and actions taken to mitigate it have had an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While it is unknown how long these conditions will last and what the financial impact will be to the Company, it is reasonably possible that future capital raising efforts and additional development of our technologies may be negatively affected.</span></p>
CY2021Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	2292	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2292	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5060
CY2021Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	3000
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	115	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1417	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3000
CY2021Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	3910000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000	usd
CY2021Q4	adtx	Units Issued During Period Shares New Issues UnitsIssuedDuringPeriodSharesNewIssues	4123	shares
CY2021Q4	adtx	Prefunded Warrants Shares PrefundedWarrantsShares	4164	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2300
CY2021Q4	adtx	Prefunded Warrants Exercise Price PrefundedWarrantsExercisePrice	0.04
CY2022Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	17200000	usd
CY2022Q3	adtx	Purchase Of Equity Shares PurchaseOfEquityShares	52725	shares
CY2022Q3	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	83333	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	240
CY2022Q3	adtx	Prefunded Warrants Exercise Price PrefundedWarrantsExercisePrice	0.04
CY2023Q2	adtx	Purchase Of Common Stock Shares Issued PurchaseOfCommonStockSharesIssued	39634	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	34.4
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9000000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3100000	usd
CY2023Q3	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	400000	usd
CY2023Q3	us-gaap	Cash Cash	1651354	usd
	us-gaap	Selling Expense SellingExpense	4800000	usd
CY2023Q2	adtx	Threshold Value For Registering Shares ThresholdValueForRegisteringShares	75000000	usd
CY2023Q1	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	35000000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	500000	usd
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the financial statements include the collectability of notes receivable, collectability and reserve on accounts receivable, the reserve on insurance billing, and the fair value of stock options and warrants.</span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentrations of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially all the Company’s accounts receivable are with companies in the healthcare industry, individuals, and the U.S. government. However, concentration of credit risk is mitigated due to the Company’s number of customers. In addition, for receivables due from U.S. government agencies, the Company does not believe the receivables represent a credit risk as these are related to healthcare programs funded by the U.S. government and payment is primarily dependent upon submitting the appropriate documentation.</span></p>
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80250	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	80250	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	18634	usd
	adtx	Licensing Fee For Patents LicensingFeeForPatents	117291	usd
	adtx	Licensing Fee For Patents LicensingFeeForPatents	256589	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	2771100	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	4186842	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26750	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3149258	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1145399	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2003859	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3134850	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	815987	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2318863	usd
CY2023Q3	us-gaap	Depreciation Depreciation	109611	usd
CY2022Q3	us-gaap	Depreciation Depreciation	99980	usd
	us-gaap	Depreciation Depreciation	329411	usd
	us-gaap	Depreciation Depreciation	296685	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1316830	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	1359091	usd
CY2020Q4	us-gaap	Equipment Expense EquipmentExpense	19487	usd
CY2021Q1	us-gaap	Equipment Expense EquipmentExpense	9733	usd
CY2021Q1	us-gaap	Equipment Expense EquipmentExpense	37171	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	321000	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	294250	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	26750	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	321000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	214000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	107000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26750	usd
CY2023Q1	adtx	Gross Proceeds GrossProceeds	1500000	usd
CY2023Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	75000	usd
CY2023Q3	us-gaap	Debt Instrument Repurchased Face Amount DebtInstrumentRepurchasedFaceAmount	77000	usd
CY2023Q2	us-gaap	Proceeds From Loans ProceedsFromLoans	2000000	usd
CY2023Q2	adtx	Future Receipts Agreement FutureReceiptsAgreement	1157143	usd
CY2023Q2	adtx	Net Proceeds NetProceeds	742857	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1060000	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	60000	usd
CY2023Q2	adtx	Net Proceeds NetProceeds	860500	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	1060000	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	60000	usd
CY2023Q2	adtx	Total Amount Of Interest And Fees Payable TotalAmountOfInterestAndFeesPayable	1590000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	2000000	usd
CY2023Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	100000	usd
CY2023Q2	adtx	Total Amount Of Interest And Fees Payable TotalAmountOfInterestAndFeesPayable	2880000	usd
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1041722	usd
CY2023Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	39286	usd
CY2023Q3	adtx	Principal Amount PrincipalAmount	215000	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	10750	usd
	adtx	Business Loan And Security Agreement BusinessLoanAndSecurityAgreement	The total amount of interest and fees payable by the Company to the Lender under the Loan (the “July Repayment Amount”) will be (i) $322,285 and will be repaid in 13 weekly installments of $24,500 with a final payment of $3,785 in the fourteenth week. As of September 30, 2023, the note was fully paid off.
CY2023Q3	us-gaap	Loans Payable LoansPayable	1400000	usd
CY2023Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	70000	usd
CY2023Q3	adtx	Total Amount Of Interest And Fees Payable TotalAmountOfInterestAndFeesPayable	2079000	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	164775	usd
CY2023Q3	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	18
CY2023Q3	us-gaap	Capital Units Total Cost To Investors CapitalUnitsTotalCostToInvestors	10066	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	963213	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	988381	usd
	us-gaap	Lease Cost LeaseCost	963213	usd
	us-gaap	Lease Cost LeaseCost	988381	usd
CY2023Q3	adtx	Right Of Use Asset Long Term RightOfUseAssetLongTerm	2454886	usd
CY2022Q4	adtx	Right Of Use Asset Long Term RightOfUseAssetLongTerm	3160457	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2454886	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	3160457	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1081377	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1086658	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1203876	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1885218	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2285253	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2971876	usd
CY2008Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y3M14D
CY2008Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	285991	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1004982	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	710546	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	423930	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2425449	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	140194	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1081377	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1203876	usd
CY2018Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	10000	shares
CY2018Q1	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2023-03-08
	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	500	shares
CY2020Q3	us-gaap	Taxes And Licenses TaxesAndLicenses	455000	usd
CY2023Q3	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	175000	usd
CY2023Q3	us-gaap	Other Commitment Due In Third Year OtherCommitmentDueInThirdYear	100000	usd
CY2023Q3	us-gaap	Other Commitment Due In Fifth Year OtherCommitmentDueInFifthYear	500000	usd
CY2023Q3	us-gaap	Other Commitment Due After Fifth Year OtherCommitmentDueAfterFifthYear	500000	usd
CY2018	us-gaap	Information Technology And Data Processing InformationTechnologyAndDataProcessing	70000	usd
CY2019Q1	us-gaap	Information Technology And Data Processing InformationTechnologyAndDataProcessing	60000	usd
	us-gaap	Product Liability Contingency Third Party Recovery Percentage ProductLiabilityContingencyThirdPartyRecoveryPercentage	0.0075	pure
	adtx	Expiration Period ExpirationPeriod	P3Y
CY2022Q1	srt	Extensions Discoveries Additions And Improved Recovery Less Related Costs ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts	100000	usd
CY2020Q1	us-gaap	Investment Company Fee Paid Indirectly InvestmentCompanyFeePaidIndirectly	25000	usd
	adtx	Stockholders Equity Other Share StockholdersEquityOtherShare	375	shares
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000	usd
	adtx	Payment Of Milestone Fees PaymentOfMilestoneFees	50000	usd
	us-gaap	Clearance Fees ClearanceFees	25000	usd
CY2020Q2	us-gaap	Financial Guarantee Insurance Contracts Accelerated Premium Revenue Amount FinancialGuaranteeInsuranceContractsAcceleratedPremiumRevenueAmount	10000000	usd
	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	In addition to the annual license maintenance fees outlined above, we are obligated pay Stanford royalties on Net Sales (as such term is defined in the February 2020 License Agreement) during the of the term of the agreement as follows: 4% when Net Sales are below or equal to $5 million annually or 6% when Net Sales are above $5 million annually.
CY2023Q2	adtx	Asset Purchase Agreement AssetPurchaseAgreement	24500000	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	14500000	usd
CY2023Q2	us-gaap	Cash Cash	10000000	usd
CY2023Q2	adtx	Payments Term PaymentsTerm	P7Y
CY2023Q3	us-gaap	Off Balance Sheet Credit Loss Liability OffBalanceSheetCreditLossLiability	1800000	usd
CY2023Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	122292	usd
CY2023Q3	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	32576	usd
CY2023Q3	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	2000000	usd
CY2023Q3	us-gaap	Loss Contingency Damages Paid Value LossContingencyDamagesPaidValue	1600000	usd
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On September 13, 2022, the Company effectuated a 1 for 50 reverse stock split (the “2022 Reverse Split”).
	us-gaap	Stock Issued During Period Shares Share Based Compensation Gross StockIssuedDuringPeriodSharesShareBasedCompensationGross	4675	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	168300	usd
CY2022Q4	adtx	Aggregate Shares Price AggregateSharesPrice	50000000	usd
	us-gaap	Insurance Commissions And Fees InsuranceCommissionsAndFees	507016	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Assets Sold Under Agreements To Repurchase Repurchase Liability AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability	20000	usd
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	250000000	shares
	us-gaap	Redemption Premium RedemptionPremium	20000	usd
CY2022Q4	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	20000	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2023Q3	us-gaap	Cash Cash	1000	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	60000	shares
CY2021Q1	adtx	Fair Market Value FairMarketValue	1	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	170	shares
CY2023Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1127	shares
	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	6802.93
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	24429	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0444	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9086	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	6128	usd
CY2023Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1000000	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10
	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	0	usd
	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	660191	usd
CY2023Q2	us-gaap	Share Price SharePrice	48.76
CY2023Q2	us-gaap	Proceeds From Loans ProceedsFromLoans	1600000	usd
CY2023Q2	us-gaap	Payments For Commissions PaymentsForCommissions	291000	usd
CY2023Q2	adtx	Exercisable Period ExercisablePeriod	P3Y
CY2023Q2	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	61
	us-gaap	Property Management Fee Percent Fee Description PropertyManagementFeePercentFeeDescription	(i) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $0.001 per share, and (ii) warrants (the “Common Warrants”) to purchase up to 1,000,000 shares of the Company’s Common Stock at an exercise price of $10.00 per share.
CY2023Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	60000	shares
CY2023Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	12.5
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y6M
CY2023Q3	adtx	Warrants Issued Black Scholes Valuation WarrantsIssuedBlackScholesValuation	1900000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9000000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	3100000	usd
CY2023Q3	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	400000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P0Y
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	993462	usd
	adtx	Share Based Payment Remnaining Expenses ShareBasedPaymentRemnainingExpenses	0	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber	170	shares
CY2023Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	157	shares
CY2023Q3	us-gaap	Deferred Costs DeferredCosts		usd
CY2022Q4	adtx	Notes Payable Related Party NotesPayableRelatedParty		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q1	adtx	Issuance Of Shares For Vested Restricted Stock Units IssuanceOfSharesForVestedRestrictedStockUnits		shares
CY2023Q2	adtx	Issuance Of Shares For Vested Restricted Stock Units IssuanceOfSharesForVestedRestrictedStockUnits		shares
CY2023Q2	adtx	Exercise Of Warrants ExerciseOfWarrants		usd
CY2023Q3	adtx	Issuance Of Restricted Stock Units For Compensation IssuanceOfRestrictedStockUnitsForCompensation		usd
CY2023Q3	adtx	Rounding From Reverse Stock Split RoundingFromReverseStockSplit		usd
CY2023Q3	adtx	Warrant Modified During Period Value WarrantModifiedDuringPeriodValue		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q1	adtx	Issuance Of Shares For Vested Restricted Stock Units IssuanceOfSharesForVestedRestrictedStockUnits		shares
CY2022Q2	adtx	Issuance Of Restricted Stock Units For Compensation IssuanceOfRestrictedStockUnitsForCompensation		usd
CY2022Q3	adtx	Warrant Modified During Period Value WarrantModifiedDuringPeriodValue		usd
CY2022Q3	adtx	Exercise Of Warrants ExerciseOfWarrants		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices		usd
	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements		usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
	adtx	Discount On Note Payable From Offering Costs DiscountOnNotePayableFromOfferingCosts		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	adtx	Debt Discount From Warrants Issued With Convertible Note Payable DebtDiscountFromWarrantsIssuedWithConvertibleNotePayable		usd
	adtx	Shares Issued For Debt Offering Costs SharesIssuedForDebtOfferingCosts		usd
	adtx	Redemption Of Series Preferred Shares To Related Party RedemptionOfSeriesPreferredSharesToRelatedParty		usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	308479	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001726711

Files In Submission

Name	View Source	Status
adtx-20230930_cal.xml	Edgar Link	unprocessable
adtx-20230930_pre.xml	Edgar Link	unprocessable
adtx-20230930_lab.xml	Edgar Link	unprocessable
0001213900-23-087099-index-headers.html	Edgar Link	pending
0001213900-23-087099-index.html	Edgar Link	pending
0001213900-23-087099.txt	Edgar Link	pending
0001213900-23-087099-xbrl.zip	Edgar Link	pending
adtx-20230930.xsd	Edgar Link	pending
f10q0923ex31-1_aditxt.htm	Edgar Link	pending
f10q0923ex31-2_aditxt.htm	Edgar Link	pending
f10q0923ex32-1_aditxt.htm	Edgar Link	pending
f10q0923_aditxtinc.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
adtx-20230930_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10q0923_aditxtinc_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADTX
Aditxt, Inc. Stock $adtx

2023 Q4 Form 10-Q Financial Statement

#000121390023087099 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADTX Aditxt, Inc. Stock $adtx

2023 Q4 Form 10-Q Financial Statement

#000121390023087099 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADTX
Aditxt, Inc. Stock $adtx